Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) CEO Bruce C. Cozadd sold 1,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $123.75, for a total transaction of $185,625.00. Following the completion of the sale, the chief executive officer now owns 440,307 shares of the company's stock, valued at $54,487,991.25. This represents a 0.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.
Jazz Pharmaceuticals Price Performance
Shares of JAZZ traded down $4.11 during mid-day trading on Tuesday, reaching $102.82. The stock had a trading volume of 1,315,463 shares, compared to its average volume of 762,522. The business has a fifty day moving average of $131.08 and a 200 day moving average of $122.86. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. The firm has a market cap of $6.24 billion, a price-to-earnings ratio of 14.48, a PEG ratio of 1.04 and a beta of 0.42. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06.
Analysts Set New Price Targets
A number of equities research analysts have commented on the stock. JPMorgan Chase & Co. lifted their target price on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an "overweight" rating in a research report on Wednesday, February 26th. Needham & Company LLC restated a "buy" rating and issued a $210.00 price target on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Barclays reiterated an "overweight" rating and set a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Morgan Stanley reissued an "overweight" rating and issued a $183.00 target price (up from $175.00) on shares of Jazz Pharmaceuticals in a research report on Friday, March 7th. Finally, HC Wainwright upped their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a "buy" rating in a research report on Monday, March 10th. One equities research analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of "Buy" and a consensus price target of $187.71.
Check Out Our Latest Stock Analysis on JAZZ
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the company. IFP Advisors Inc purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth $25,000. Quadrant Capital Group LLC boosted its holdings in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after purchasing an additional 101 shares during the last quarter. Elequin Capital LP boosted its holdings in shares of Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock valued at $26,000 after purchasing an additional 183 shares during the last quarter. CoreFirst Bank & Trust purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter valued at about $28,000. Finally, Allianz SE bought a new stake in shares of Jazz Pharmaceuticals in the fourth quarter worth about $29,000. Institutional investors own 89.14% of the company's stock.
About Jazz Pharmaceuticals
(
Get Free Report)
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.
Featured Stories
Before you consider Jazz Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jazz Pharmaceuticals wasn't on the list.
While Jazz Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
